James S Minnion

List of Publications by Year
in descending order

98 papers	8,399 citations	117571 34 h-index	46771 89 g-index
98 all docs	98 docs citations	98 times ranked	7872 citing authors

#	Article	IF	Citations
1	The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e767-e782.	1.8	16
2	Genetic and biased agonist-mediated reductions in Î²-arrestin recruitment prolong cAMP signaling at glucagon family receptors. Journal of Biological Chemistry, 2021, 296, 100133.	1.6	41
3	Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking. Molecular Pharmacology, 2021, 100, 319-334.	1.0	13
4	Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1. Biochemical Pharmacology, 2021, 190, 114656.	2.0	8
5	Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist. Molecular Metabolism, 2021, 51, 101242.	3.0	7
6	Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling. Molecular Metabolism, 2021, 53, 101296.	3.0	23
7	A glucagon analogue decreases body weight in mice via signalling in the liver. Scientific Reports, 2021, 11, 22577.	1.6	6
8	Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 833-838.	1.8	3
9	Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells. International Journal of Molecular Sciences, 2020, 21, 8404.	1.8	28
10	CBD Effects on TRPV1 Signaling Pathways in Cultured DRG Neurons . Journal of Pain Research, 2020, Volume 13, 2269-2278.	0.8	36
11	Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1119-1125.	1.8	11
12	Resistance to lean mass gain in constitutional thinness in freeâ€living conditions is not overpassed by overfeeding. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1187-1199.	2.9	14
13	Disconnect between signalling potency and inÂvivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. Molecular Metabolism, 2020, 37, 100991.	3.0	32
14	The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists. ACS Pharmacology and Translational Science, 2020, 3, 345-360.	2.5	32
15	Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1899-1905.	1.8	3
16	Signalling, trafficking and glucoregulatory properties of glucagonâ€like peptideâ€1 receptor agonists exendinâ€4 and lixisenatide. British Journal of Pharmacology, 2020, 177, 3905-3923.	2.7	36
17	Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells. PLoS Biology, 2019, 17, e3000097.	2.6	61
18	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. Diabetes Care, 2019, 42, 1446-1453.	4.3	84

#	Article	IF	Citations
19	What Can We Learn From Mouse Models About Bile Acidâ€“Mediated Changes After Bariatric Surgery?. Gastroenterology, 2019, 157, 4-8.	0.6	7
20	Bile acids and the metabolic syndrome. Annals of Clinical Biochemistry, 2019, 56, 326-337.	0.8	91
21	SUN-LB044 Effects of Glucagon-Like Peptide-1 (GLP-1) on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men. Journal of the Endocrine Society, 2019, 3, .	0.1	1
22	Reply: Clinical trial registry alone is not adequate: on the perception of possible endpoint switching and P-hacking. Human Reproduction, 2018, 33, 342-344.	0.4	1
23	Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nature Communications, 2018, 9, 1602.	5.8	162
24	Influence of Cholecystokinin-8 on Compound Nerve Action Potentials from Ventral Gastric Vagus in Rats. International Journal of Neural Systems, 2018, 28, 1850006.	3.2	7
25	Control of insulin secretion by GLP-1. Peptides, 2018, 100, 75-84.	1.2	69
26	A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic Î²-Cells. Diabetes, 2018, 67, 385-399.	0.3	41
27	Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions. JCI Insight, 2018, 3, .	2.3	26
28	Lâ€Arginine Increases Postprandial Circulating GLPâ€1 and PYY Levels in Humans. Obesity, 2018, 26, 1721-1726.	1.5	18
29	No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century. Frontiers in Endocrinology, 2018, 9, 442.	1.5	22
30	Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases. Endocrinology, 2017, 158, 1755-1765.	1.4	16
31	Potent Prearranged Positive Allosteric Modulators of the Glucagonâ€like Peptideâ€1 Receptor. ChemistryOpen, 2017, 6, 501-505.	0.9	31
32	RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling. Endocrinology, 2017, 158, 2680-2693.	1.4	33
33	Thyroid Hormone Receptor Beta in the Ventromedial Hypothalamus Is Essential for the Physiological Regulation of Food Intake and Body Weight. Cell Reports, 2017, 19, 2202-2209.	2.9	25
34	Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 389, 1809-1820.	6.3	149
35	The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2364-2372.	1.8	72
36	Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. European Journal of Endocrinology, 2017, 177, 455-464.	1.9	50

#	Article	IF	Citations
37	A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Human Reproduction, 2017, 32, 1915-1924.	0.4	64
38	Differentiating constitutional thinness from anorexia nervosa in DSM 5 era. Psychoneuroendocrinology, 2017, 84, 94-100.	1.3	35
39	The preanalytical stability of glucagon as measured by liquid chromatography tandem mass spectrometry and two commercially available immunoassays. Annals of Clinical Biochemistry, 2017, 54, 293-296.	0.8	9
40	Fermentable carbohydrate stimulates FFAR2-dependent colonic PYY cell expansionÂtoÂincrease satiety. Molecular Metabolism, 2017, 6, 48-60.	3.0	179
41	Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. Journal of Investigative Surgery, 2017, 30, 162-169.	0.6	1
42	Allosterische optische Steuerung eines Klasseâ€Bâ€Gâ€Proteinâ€gekoppelten Rezeptors. Angewandte Chemie, 2016, 128, 5961-5965.	1.6	10
43	Subcutaneous infusion of kisspeptinâ€54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels. Clinical Endocrinology, 2016, 84, 939-945.	1.2	31
44	Kisspeptin Expression in the Human Infundibular Nucleus in Relation to Sex, Gender Identity, and Sexual Orientation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2380-2389.	1.8	32
45	Investigating the KNDy Hypothesis in Humans by Coadministration of Kisspeptin, Neurokinin B, and Naltrexone in Men. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3429-3436.	1.8	37
46	Insights into the role of neuronal glucokinase. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E42-E55.	1.8	33
47	Allosteric Optical Control of a Class B Gâ€Proteinâ€Coupled Receptor. Angewandte Chemie - International Edition, 2016, 55, 5865-5868.	7.2	45
48	Kisspeptin signaling in the amygdala modulates reproductive hormone secretion. Brain Structure and Function, 2016, 221, 2035-2047.	1.2	66
49	Proglucagon Promoter Cre-Mediated AMPK Deletion in Mice Increases Circulating GLP-1 Levels and Oral Glucose Tolerance. PLoS ONE, 2016, 11, e0149549.	1.1	13
50	Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats. Current Therapeutic Research, 2015, 77, 111-115.	0.5	7
51	Neurokinin B Administration Induces Hot Flushes in Women. Scientific Reports, 2015, 5, 8466.	1.6	96
52	Optical Control of Insulin Secretion Using an Incretin Switch. Angewandte Chemie - International Edition, 2015, 54, 15565-15569.	7.2	80
53	Increased food intake with oxyntomodulin analogues. Peptides, 2015, 73, 95-100.	1.2	6
54	The identification of elevated urinary kisspeptin-immunoreactivity during pregnancy. Annals of Clinical Biochemistry, 2015, 52, 395-398.	0.8	11

#	Article	IF	Citations
55	The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. Drugs, 2015, 75, 935-945.	4.9	46
56	Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3â€“36 and its analogues in vivo. Lancet, The, 2015, 385, S28.	6.3	4
57	Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3322-3331.	1.8	135
58	Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut, 2015, 64, 1744-1754.	6.1	950
59	Learning curve of vessel cannulation in rats using cumulative sum analysis. Journal of Surgical Research, 2015, 193, 69-76.	0.8	3
60	Patient Age Predicts the Delay before Survivors of Cancer Utilise Their Cryopreserved Sperm for Assisted Reproductive Technology. Blood, 2015, 126, 4481-4481.	0.6	0
61	Colocalization of Cocaine- and Amphetamine-Regulated Transcript with Kisspeptin and Neurokinin B in the Human Infundibular Region. PLoS ONE, 2014, 9, e103977.	1.1	21
62	Combination of Peptide YY_{3â€“36}with GLP-1_{7â€“36 amide}Causes an Increase in First-Phase Insulin Secretion after IV Glucose. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2317-E2324.	1.8	27
63	The Peutz-Jeghers kinase LKB1 suppresses polyp growth from intestinal cells of a proglucagon-expressing lineage. DMM Disease Models and Mechanisms, 2014, 7, 1275-86.	1.2	10
64	Ghrelin mimics fasting to enhance human hedonic, orbitofrontal cortex, and hippocampal responses to food. American Journal of Clinical Nutrition, 2014, 99, 1319-1330.	2.2	116
65	Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake. Diabetes, 2014, 63, 3711-3720.	0.3	119
66	The effect of slow spaced eating on hunger and satiety in overweight and obese patients with type 2 diabetes mellitus. BMJ Open Diabetes Research and Care, 2014, 2, e000013.	1.2	28
67	Quantification of Rat Kisspeptin Using a Novel Radioimmunoassay. PLoS ONE, 2014, 9, e97611.	1.1	11
68	Obesity, gut hormones and knighthood. Expert Review of Endocrinology and Metabolism, 2013, 8, 225-227.	1.2	0
69	Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. Diabetes, 2013, 62, 1131-1138.	0.3	182
70	Hypothalamic neuropeptides and the regulation of appetite. Neuropharmacology, 2012, 63, 18-30.	2.0	199
71	Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. British Journal of Clinical Pharmacology, 2012, 73, 232-239.	1.1	30
72	Pharmacotherapy for obesity: a field in crisis?. Expert Review of Endocrinology and Metabolism, 2011, 6, 563-577.	1.2	4

#	Article	IF	Citations
73	Intracerebroventricular administration of vasoactive intestinal peptide inhibits food intake. Regulatory Peptides, 2011, 172, 8-15.	1.9	20
74	The effects of kisspeptinâ€54 on blood pressure in humans and plasma kisspeptin concentrations in hypertensive diseases of pregnancy. British Journal of Clinical Pharmacology, 2010, 70, 674-681.	1.1	30
75	Approaches to the pharmacological treatment of obesity. Expert Review of Clinical Pharmacology, 2010, 3, 73-88.	1.3	10
76	Appetite and Hedonism: Gut Hormones and the Brain. Endocrinology and Metabolism Clinics of North America, 2010, 39, 729-743.	1.2	18
77	Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs. Endocrinology, 2009, 150, 1712-1721.	1.4	77
78	Ghrelin and peptide YY (PYY) profiles in gastrointestinal tissues and the circulation of the rat during pregnancy and lactation. Peptides, 2009, 30, 2213-2220.	1.2	20
79	Peripheral and Central Administration of Xenin and Neurotensin Suppress Food Intake in Rodents. Obesity, 2009, 17, 1135-1143.	1.5	89
80	Does Kisspeptin signaling offer a new way to treat infertility?. Expert Review of Obstetrics and Gynecology, 2009, 4, 477-481.	0.4	0
81	Overexpression of CART in the PVN Increases Food Intake and Weight Gain in Rats. Obesity, 2008, 16, 2239-2244.	1.5	44
82	Introductory chapter. , 2008, , 1-19.		0
83	The Obesity Epidemic: Pharmacological Challenges. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2008, 8, 82-98.	3.4	49
84	The neuroendocrine physiology of kisspeptin in the human. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 41-46.	2.6	38
85	Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. American Journal of Clinical Nutrition, 2007, 86, 1603-1610.	2.2	30
86	Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obesity Surgery, 2007, 17, 1193-1198.	1.1	2
87	Oxyntomodulin. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 265-272.	1.8	23
88	Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochemical and Biophysical Research Communications, 2006, 350, 298-306.	1.0	73
89	The inhibitory effects of peripheral administration of peptide YY3â€“36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagalâ€“brainstemâ€“hypothalamic pathway. Brain Research, 2005, 1044, 127-131.	1.1	494
90	Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects: A Double-Blind, Randomized, Controlled Trial. Diabetes, 2005, 54, 2390-2395.	0.3	383

#	Article	IF	Citations
91	Postembryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype. FASEB Journal, 2005, 19, 1680-1682.	0.2	215
92	Peripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in Rats. Endocrinology, 2004, 145, 2687-2695.	1.4	285
93	Abnormalities of the hypothalamo-pituitary-thyroid axis in the pro-opiomelanocortin deficient mouse. Regulatory Peptides, 2004, 122, 169-172.	1.9	13
94	Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4696-4701.	1.8	406
95	Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E1173-E1177.	1.8	116
96	Gut hormone PYY3-36 physiologically inhibits food intake. Nature, 2002, 418, 650-654.	13.7	2,039
97	Cheap date. Nature, 1998, 396, 313-314.	13.7	6
98	EFFECT OF OCTAPEPTIDE SOMATOSTATIN ANALOGUE (SMS 201â€995) ON PLASMA 7B2 (A NEUROENDOCRINE) Tj ETQq0 0 0 rgBT /Ov	1.2	4